| |
|
|
|
|
|
|
|||
|
Blood, 28 May 2009, Vol. 113, No. 22, pp. 5476-5479. Prepublished online as a Blood First Edition Paper on March 18, 2009; DOI 10.1182/blood-2009-02-204800.
HEMATOPOIESIS AND STEM CELLS Generation of induced pluripotent stem cells from human blood1 Department of Medicine, Division of Pediatric Hematology Oncology, Children's Hospital Boston, Dana-Farber Cancer Institute, and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA; 2 Harvard Stem Cell Institute, Cambridge, MA; 3 Howard Hughes Medical Institute, Boston, MA; 4 Division of Hematology, Brigham and Women's Hospital, Boston, MA; and 5 Manton Center for Orphan Disease Research, Boston, MA Human dermal fibroblasts obtained by skin biopsy can be reprogrammed directly to pluripotency by the ectopic expression of defined transcription factors. Here, we describe the derivation of induced pluripotent stem cells from CD34+ mobilized human peripheral blood cells using retroviral transduction of OCT4/SOX2/KLF4/MYC. Blood-derived human induced pluripotent stem cells are indistinguishable from human embryonic stem cells with respect to morphology, expression of surface antigens, and pluripotency-associated transcription factors, DNA methylation status at pluripotent cell-specific genes, and the capacity to differentiate in vitro and in teratomas. The ability to reprogram cells from human blood will allow the generation of patient-specific stem cells for diseases in which the disease-causing somatic mutations are restricted to cells of the hematopoietic lineage.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2009 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||